NRAS and neuroblastoma: Notably, recent evidence regarding the use of a PTPN11 inhibitor in NRAS-mutated NB, showed increased survival and a decreased tumour volume in preclinical models; this evidence suggests that the RAS/MAPK pathway may be an effective therapeutic target for this malignancy32.